These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 5774043)

  • 1. A study of the role of noradrenaline in behavioral changes produced in the rat by psychotomimetic drugs.
    Sugrue MF
    Br J Pharmacol; 1969 Feb; 35(2):243-52. PubMed ID: 5774043
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The possible role of tryptamine in brain function and its relationship to the actions of LSD-like hallucinogens.
    Martin WR; Sloan JW
    Mt Sinai J Med; 1974; 41(2):276-82. PubMed ID: 4544624
    [No Abstract]   [Full Text] [Related]  

  • 3. Some observations on the behavioural effects of hallucinogenic drugs on rats: potentiation by two drugs affecting monoamine metabolism.
    Tonge SR; Leonard BE
    Arch Int Pharmacodyn Ther; 1972 Jan; 195(1):168-76. PubMed ID: 5010826
    [No Abstract]   [Full Text] [Related]  

  • 4. Psilocybin as a discriminative stimulus: lack of specificity in an animal behavior model for 'hallucinogens'.
    Koerner J; Appel JB
    Psychopharmacology (Berl); 1982; 76(2):130-5. PubMed ID: 6805022
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An animal behavior model for studying the actions of LSD and related hallucinogens.
    Jacobs BL; Trulson ME; Stern WC
    Science; 1976 Nov; 194(4266):741-3. PubMed ID: 982043
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Psychopsychic correlations under the effect of psycholytics (LSD, psilocybin and similar drugs)].
    HOLFELD H
    Med Exp Int J Exp Med; 1961; 5():209-14. PubMed ID: 13908338
    [No Abstract]   [Full Text] [Related]  

  • 7. Psilocybin-induced stimulus control in the rat.
    Winter JC; Rice KC; Amorosi DJ; Rabin RA
    Pharmacol Biochem Behav; 2007 Oct; 87(4):472-80. PubMed ID: 17688928
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Behavioural effects of some derivatives of amphetamine and LSD and their significance.
    Smythies JR; Beaton J; Benington F; Morin RD
    Nature; 1970 May; 226(5246):644-5. PubMed ID: 5444927
    [No Abstract]   [Full Text] [Related]  

  • 9. [Electrographic and behavioral effects of various hallucinogens in the free cat].
    Rougeul A; Verdeaux J; Letalle A
    Rev Neurol (Paris); 1969 Jun; 120(6):391-4. PubMed ID: 5379317
    [No Abstract]   [Full Text] [Related]  

  • 10. Nerve terminal effects of indoleamine psychotomimetics on 5-hydroxytryptamine.
    Halaris AE
    Neurosci Biobehav Rev; 1982; 6(4):483-7. PubMed ID: 6294571
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A comparison of psychotomimetic drug effects on rat brain norepinephrine metabolism.
    Stolk JM; Barchas JD; Goldstein M; Boggan W; Freedman DX
    J Pharmacol Exp Ther; 1974 Apr; 189(1):42-50. PubMed ID: 4823298
    [No Abstract]   [Full Text] [Related]  

  • 12. d-Lysergic acid diethylamide, psilocybin, and other classic hallucinogens: Mechanism of action and potential therapeutic applications in mood disorders.
    De Gregorio D; Enns JP; Nuñez NA; Posa L; Gobbi G
    Prog Brain Res; 2018; 242():69-96. PubMed ID: 30471683
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of isolation-induced attack behavior of mice by drugs.
    Uyeno ET
    J Pharm Sci; 1966 Feb; 55(2):215-6. PubMed ID: 5923276
    [No Abstract]   [Full Text] [Related]  

  • 14. Pharmacological studies on para-bromo-methamphetamine (V-111) and LSD.
    Knoll J; Vizi ES; Knoll B
    Acta Physiol Acad Sci Hung; 1970; 37(1):151-70. PubMed ID: 5433553
    [No Abstract]   [Full Text] [Related]  

  • 15. Facilitation of avoidance behaviour by LSD-25 and mescaline in hamsters.
    Sansone M; Castellano C; Messeri P
    Pharmacol Res Commun; 1974 Aug; 6(4):369-76. PubMed ID: 4438404
    [No Abstract]   [Full Text] [Related]  

  • 16. Comparison of the reactions induced by psilocybin and LSD-25 in man.
    ISBELL H
    Psychopharmacologia; 1959; 1():29-38. PubMed ID: 14405870
    [No Abstract]   [Full Text] [Related]  

  • 17. Inhibitory effects of lysergic acid derivatives and reserpine on 5-HT binding to nerve ending particles.
    Marchbanks RM
    Biochem Pharmacol; 1967 Oct; 16(10):1971-9. PubMed ID: 6065963
    [No Abstract]   [Full Text] [Related]  

  • 18. Cross tolerance between LSD and psilocybin.
    ISBELL H; WOLBACH AB; WIKLER A; MINER EJ
    Psychopharmacologia; 1961; 2():147-59. PubMed ID: 13717955
    [No Abstract]   [Full Text] [Related]  

  • 19. Development of the Psychological Insight Questionnaire among a sample of people who have consumed psilocybin or LSD.
    Davis AK; Barrett FS; So S; Gukasyan N; Swift TC; Griffiths RR
    J Psychopharmacol; 2021 Apr; 35(4):437-446. PubMed ID: 33427007
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Illicit use of LSD or psilocybin, but not MDMA or nonpsychedelic drugs, is associated with mystical experiences in a dose-dependent manner.
    Lyvers M; Meester M
    J Psychoactive Drugs; 2012; 44(5):410-7. PubMed ID: 23457892
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.